Please login to the form below
Xeljanz
This page shows the latest Xeljanz news and features for those working in and with pharma, biotech and healthcare.
Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb
Sales of Pfizer’s immunology medicine Xeljanz were down by 15%, driven partly by a negative impact on new patients starting the therapy following an ongoing US Food and Drug Administration
Latest news
-
Pfizer’s COVID-19 vaccine yields $3.5bn in first quarter sales
Pfizer’s Janus kinase (JAK) inhibitor Xeljanz also grew by 18% operationally, with a 16% growth in the US and a 21% increase in international markets, thanks to uptake in the
-
FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz
Post-marketing study shows increased risk of serious heart-related problems and cancer with Xeljanz. ... In addition, 122 patients receiving Xeljanz treatment developed cancer, versus 42 for those taking TNF inhibitors.
-
Pfizer, Sanofi and others set to increase US drug prices in 2021
Pfizer, in particular, aims to raise prices on over 60 drugs by between 0.5% and 5%, with an approximate 5% increase on some blockbuster treatments including Xeljanz (tofacitinib) and cancer
-
Incyte’s JAK inhibitor cream clears second eczema trial
The latter group includes Pfizer’s Xeljanz, (tofacitinib), Eli Lilly’s Olumiant (baricitinib) and AbbVie’s Rinvoq (upadacitinib), which have been approved for rheumatoid arthritis but are also in testing for
-
Skyrizi, Rinvoq help AbbVie weather Humira slowdown
Meanwhile, selective JAK inhibitor Rinvoq added another $33m from its first approval in rheumatoid arthritis, as it took on market leader Xeljanz (tofacitinib) from Pfizer, which showed the first signs of
Pfizer’s COVID-19 vaccine yields $3.5bn in first quarter sales
FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz
Pfizer, Sanofi and others set to increase US drug prices in 2021
Incyte’s JAK inhibitor cream clears second eczema trial
Skyrizi, Rinvoq help AbbVie weather Humira slowdown
More from news
Approximately 20 fully matching, plus 66 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
JAK inhibitors such as Xeljanz and Rinvoq.
-
20 for 2020 – Five pharma leaders to watch in 2020
to 2025 built on the Prevnar franchise, rare disease therapy Vyndaqel (tafamidis), breast cancer therapy Ibrance (palbociclib) and arthritis drug Xeljanz (tofacitinib), among others.
-
Pharma deals during September 2013
antibody (MAb) Actemra and Pfizer's JAK inhibitor Xeljanz.
Cortellis Drugs to Watch in 2020 report
20 for 2020 – Five pharma leaders to watch in 2020
Pharma deals during September 2013
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Webcast: Navigating new frontiers: Ways to find space in the future RA market
In partnership with pharmaphorum. Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely
-
Live webinar: Navigating new frontiers: Ways to find space in the future RA market
Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case
-
Infographic: RA Perceptions
The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’s Otezla (apremilast) and Pfizer’s Xeljanz (tofacitinib), which both offer a new oral alternative ... Of the physicians who were familiar with
-
Brand leaders in RA will lose market share, predict rheumatologists
JAK-inhibitors were the most commonly mentioned class, with Xeljanz the most frequently cited product. . ... The EMA’s refusal to grant a marketing authorisation for Xeljanz was disappointing for Pfizer, however, the drug is said to be performing in
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Senior Account Manager
-
Competitive salary offered
-
CEO, Head of Health, UK
-
Six figure salary
-
Omnichannel Strategy Consultant
-
Competitive Salary
-
CEO Pricing & Market Access, UK
-
Six figure salary
- Valneva COVID-19 vaccine more effective than AZ
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
- Biogen's ALS drug tofersen misses phase 3 endpoint
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Merck’s COVID-19 antiviral under review in Europe by EMA
- AZ’s Imfinzi boosts survival in biliary tract cancer
- MAKING THE FIRST YEAR MATTER
- Merck receives first breast cancer approval in Europe for Keytruda
- Benefits of COVID-19 vaccine in younger children outweigh risks, says FDA
- Call for industry innovators to join working group
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb
- Curb your conservatism: can pharma ditch its cautious approach to creativity in comms?
- Amgen strikes $240m autoimmune deal with Evoq Therapeutics
- Award-winning health agency 90TEN launches in the US
PMHub
Lucid Group Communications Limited
WE’RE ON A MISSION
To transform lives through communication that changes behaviour and improves health outcomes....
Latest intelligence
- The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
- The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
- Mind the Gap – Challenging Immunisation Apathy and Misinformation
- world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
- Towards Better HCP Engagement – An Email Masterclass
- 6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....
